ALEXANDRIA, Va., April 21 -- United States Patent no. 12,606,826, issued on April 21, was assigned to Ionis Pharmaceuticals Inc. (Carlsbad, Calif.).
"Modulation of transthyretin expression" was invented by Susan M. Freier (San Diego).
According to the abstract* released by the U.S. Patent & Trademark Office: "Provided herein are methods, compounds, and compositions for reducing expression of transthyretin mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate transthyretin amyloidosis, or a symptom thereof."
The patent was filed on Dec. 2, 2022, under Application No. 18/060,965.
*For further information, including images, charts and tables, please visit: http://patft.u...